Drug Profile
Research programme: infectious disease therapeutics - Theriva Biologics/Precigen Inc
Alternative Names: anti-Acinetobacter mAbs - Theriva Biologics/Precigen Inc; anti-pertussis mAbs - Theriva Biologics/Precigen Inc; hu1B7; hu1B7-YTE; Pertussis (whooping cough) monoclonal antibody - Theriva Biologics; SYN-001Latest Information Update: 14 Oct 2022
Price :
$50
*
At a glance
- Originator Intrexon Corporation; Synthetic Biologics
- Developer Precigen Inc; Theriva Biologics; University of Texas at Austin
- Class Anti-infectives; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acinetobacter infections; Infections; Inflammatory bowel diseases; Pertussis; Phenylketonuria
Most Recent Events
- 12 Oct 2022 Synthetic Biologics is now called Theriva Biologics
- 28 Sep 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Pertussis in USA (Parenteral)